SCM
NMRA icon

Soros Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Soros Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-279,333
Closed -$2.96M – 67
2024
Q4 		$2.96M Sell
279,333
-229,580
-45% -$2.75M 0.46% 46
2024
Q3 		$6.72M Hold
508,913
– – 1.62% 23
2024
Q2 		$5M Sell
508,913
-395,103
-44% -$4.09M 2.19% 11
2024
Q1 		$12.4M Buy
+904,016
New +$14.6M 2.28% 15
2023
Q4 		– Sell
-588,235
Closed -$8.3M – 38
2023
Q3 		$8.3M Buy
+588,235
New +$7.35M 3.48% 11

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Soros Capital Management's NMRA Position: Q1 2025 in Review

Soros Capital Management sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 279,333 shares — an estimated $2.96M sold.

Soros Capital Management first reported a position in NMRA in Q3 2023 and held it in 5 quarters. The position peaked at $12.4M in Q1 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Soros Capital Management reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Soros Capital Management sold 279,333 Neumora Therapeutics shares in Q1 2025, an estimated $2.96M.
  • Soros Capital Management first reported a position in Neumora Therapeutics in Q3 2023 and held it in 5 quarters.
  • Soros Capital Management's Neumora Therapeutics position peaked at $12.4M in Q1 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Soros Capital Management's 13F filing for Q1 2025, filed 14 May 2025.